title: Surgery for cholangiocarcinoma: the role of liver transplantation.
abstract: Liver transplantation alone for unresectable hilar cholangiocarcinoma (CCA) is fraught with frequent recurrence and poor long-term survival. The Mayo Clinic developed a novel therapeutic protocol combining neoadjuvant chemoradiation and orthotopic liver transplantation (OLT) in 1993 to treat patients with unresectable hilar CCA or CCA arising in the setting of PSC.
  
  
  OBJECTIVE
  We recently reviewed our experience over the past 14 years with the specific aim to evaluate the long-term outcomes of CCA patients treated according to our study protocol.
  
  
  METHODS
  We analyzed data from all patients enrolled in the Mayo Clinic liver transplant protocol since 1993. Statistical data analysis of recurrence and survival rates was performed using the Kaplan-Meier method.
  
  
  RESULTS
  148 patients were enrolled in the protocol. Of 90 patients who completed neoadjuvant therapy and subsequent OLT, 71 are alive and 19 have died--only 8 due to recurrent CCA. Nineteen patients are awaiting OLT and 39 were removed from the protocol owing to disease progression or death. Overall, 1-, 3-, and 5-year patient survival was 82%, 63%, and 55%, respectively; 1-, 3-, and 5-year survival after OLT was 90%, 80%, and 71%.
  
  
  CONCLUSIONS
  Neoadjuvant chemoradiation and OLT achieves significantly lower recurrence and higher long-term survival rates than resection, OLT alone, or medical treatment in hilar CCA. Additional experience at independent transplant centers is necessary to confirm these encouraging results, address the role of neoadjuvant therapy and liver transplantation versus conventional resection, determine appropriate inclusion/exclusion criteria, and define the risk of disease progression while awaiting transplantation.
authors.affiliation: Department of Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA. rosen.charles@mayo.edu
authors.forename: C B
authors.initials: CB
authors.lastname: Rosen
authors.forename: J K
authors.initials: JK
authors.lastname: Heimbach
authors.forename: G J
authors.initials: GJ
authors.lastname: Gores
references.citation: Cancer. 2003 Oct 15;98(8):1689-700
references.pmid: 14534886
references.citation: Ann Surg. 1991 Jan;213(1):21-5
references.pmid: 1845927
references.citation: Ann Surg. 2004 Feb;239(2):265-71
references.pmid: 14745336
references.citation: Semin Liver Dis. 2004 May;24(2):201-7
references.pmid: 15192792
references.citation: Am J Surg. 1993 Dec;166(6):768-71; discussion 771-2
references.pmid: 8273866
references.citation: J Hepatol. 2004 May;40(5):815-22
references.pmid: 15094230
references.citation: Semin Surg Oncol. 2000 Sep-Oct;19(2):156-76
references.pmid: 11126380
references.citation: J Am Coll Surg. 1995 Jan;180(1):1-9
references.pmid: 8000645
references.citation: Langenbecks Arch Surg. 2003 Jul;388(3):194-200
references.pmid: 12819970
references.citation: Surgery. 2006 Sep;140(3):331-4
references.pmid: 16934588
references.citation: Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61
references.pmid: 16135931
references.citation: Liver Transpl. 2000 May;6(3):309-16
references.pmid: 10827231
references.citation: Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):929-35
references.pmid: 9369143
references.citation: Liver Transpl. 2005 Nov;11(11):1412-6
references.pmid: 16237695
references.citation: Am J Transplant. 2002 Sep;2(8):774-9
references.pmid: 12243499
references.citation: Mayo Clin Proc. 1995 May;70(5):425-9
references.pmid: 7537346
references.citation: Am J Gastroenterol. 2004 Mar;99(3):523-6
references.pmid: 15056096
references.citation: Liver Transpl. 2006 Dec;12(12 Suppl 3):S95-7
references.pmid: 17123289
references.citation: Transplantation. 2006 Dec 27;82(12):1703-7
references.pmid: 17198263
references.citation: Transplantation. 2000 Apr 27;69(8):1633-7
references.pmid: 10836374
references.citation: Liver Transpl. 2001 Dec;7(12):1023-33
references.pmid: 11753904